Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 27;11:62. doi: 10.1186/s13229-020-00358-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 8 — Treatment with fenofibrate affected the expression of pre- and postsynaptic markers in the CPu of VPA-exposed rats. The excitatory glutamatergic and inhibitory GABAergic nerve terminals in the CPu region were determined by immunoblotting of vesicular glutamatergic (vGLUT) and GABAergic (vGAT) transporters, respectively, in males (a, b) and females (e, f), and the vGLUT/vGAT ratio was calculated (c, g) as an indication of excitatory/inhibitory synaptic balance. a Two-way ANOVA, VPA exposure: F_1,25 = 6.10, p = 0.0207; FBR administration: F_1,25 = 0.033, n.s.; interaction: F_1,25 = 0.002, n.s. b Two-way ANOVA, VPA exposure: F_1,25 = 0.0001, n.s.; FBR administration: F_1,25 = 0.037, n.s.; interaction: F_1,25 = 2.21, n.s. c Two-way ANOVA, VPA exposure: F_1,25 = 20.93, p = 0.0001; FBR administration: F_1,25 = 2.87, n.s.; interaction: F_1,25 = 16.17, p = 0.0005; post hoc comparison: ***p < 0.001 VPA-SD vs. saline-SD group; ^##p < 0.01 vs. VPA-SD group. d Representative immunoblotting of v-GLUT and v-GAT in male. e Two-way ANOVA, VPA exposure: F_1,21 = 0.94, n.s; FBR administration: F_1,21 = 1.10, n.s.; interaction: F_1,21 = 4.16, n.s. f Two-way ANOVA, VPA exposure: F_1,21 = 0.168, n.s.; FBR administration: F_1,21 = 0.016, n.s.; interaction: F_1,21 = 0.086, n.s. g Two-way ANOVA, VPA exposure: F_1,21 = 0.026, n.s.; FBR administration: F_1,21 = 0.89, n.s.; interaction: F_1,21 = 4.06, n.s. h Representative immunoblotting of v-GLUT and v-GAT in female. The levels of PSD-95 were measured in the CPu by immunoblotting in male (i) and female rats (k). i Two-way ANOVA, VPA exposure: F_1,25 = 19.22, p = 0.0002.; FBR administration: F_1,25 = 2.67, n.s.; interaction: F_1,25 = 1.50, n.s. j Representative immunoblotting of PSD-95 in male rats. k Two-way ANOVA, VPA exposure: F_1,21 = 3.18, n.s.; FBR administration: F_1,21 = 3.53, n.s.; interaction: F_1,21 = 41.030, n.s. l Representative immunoblotting of PSD-95 in female rats. Values are expressed as mean ± SEM and calculated as percentage of the respective saline-SD group values; n = 6–8